Basic Information
(As of April 1, 2024)
| Company name | ASKA Pharmaceutical Co., Ltd. |
|---|---|
| Address | |
| Founded | June 16, 1920 |
| Established | June 28, 1929 |
| Business segments | Manufacturing, sale and import/export of pharmaceuticals, veterinary medicines, quasi-drugs, foods, and medical devices, etc. |
| Representative | Sohta Yamaguchi President, Representative Director |
| Executives | Please see the list of Executives. |
| Business locations | Please see the list of Offices and Group Companies for locations. |
| Group companies | Please see the list of Offices and Group Companies for information on group companies. |
| Capital | ¥1,197.9 million |
| Number of employees | 627 (101)* |
| Main Bank | MUFG Bank, Ltd. |
| URL | https://www.aska-pharma.co.jp/english/ |
- *Number of employees is the number of full-time employees who actually work as of March 31, 2024. Figures in parentheses represent the average number of temporary employees during the year and are not included in the number of full-time employees.
Organization Chart
(As of April 1, 2025)
History
| June 1920 |
Founder Yasohachi Yamaguchi established Teikoku Hormone Research Institute in Minami Yoshidamachi, Yokohama |
|---|---|
| June 1921 |
Launched SPERMATIN, a male gonadal hormone agent |
| July 1922 |
Launched THYRADIN, a Hypothyroidism agent |
| June 1929 |
Reorganized as a corporation, Teikoku Hormone Mfg. Research Laboratory Co., Ltd. |
| January 1936 |
Constructed Takatsu Factory (Kawasaki Research Center) in Kawasaki-shi (former Tachibana-gun), Kanagawa |
| October 1945 |
Changed company name to Teikoku Hormone Mfg. Co., Ltd. |
| October 1946 |
Moved the Head Office to Nishi-Shinbashi, Minato-ku, Tokyo (formerly Shiba-Minamisakuma-cho, Shiba-ku, Tokyo) |
| January 1952 |
Appointed Eiichi Yamaguchi as President |
| September 1955 |
Listed on the Tokyo Stock Exchange |
| June 1957 |
Began veterinary pharmaceutical production and sales |
| November 1962 |
Moved the Head Office to Akasaka, Minato-ku, Tokyo |
| August 1971 |
Started clinical testing business |
| July 1975 |
Started medical equipment business |
| April 1980 |
Constructed Iwaki Factory in Iwaki, Fukushima |
| September 1981 |
Launched PROSTAL TABLETS, a benign prostatic hyperplasia treatment (Indication for prostate cancer added in May 1983) |
| October 1986 |
Launched ALTAT CAPSULES, a gastritis agent (Indication for gastric ulcer added in June 1993) |
| May 1991 |
Established Medical System Service Kanagawa, Inc. (now ASKA Pharma Medical Co., Ltd.) |
| June 1991 |
Appointed Takashi Yamaguchi as President |
| April 1997 |
Established the International Representative Office in Frankfurt, Germany |
| September 1999 |
Launched ANGE, an oral contraceptive |
| June 2000 |
80th anniversary |
| September 2001 |
Constructed and moved the Head Office building in Shibaura, Minato-ku, Tokyo |
| March 2005 |
Launched LIPIDIL capsules, a hyperlipidemic agent |
| October 2005 |
Merged with Teikoku Hormone and Grelan, changed company name as ASKA Pharmaceutical Co., Ltd. |
| May 2011 |
Launched NORLEVO TABLET, an emergency contraceptive |
| December 2011 |
Launched LIPIDIL TABLETS, a hyperlipidemic agent |
| April 2013 |
Completed the Quality Control Building in Iwaki Factory |
| June 2013 |
Established ASKA Animal Health Co., Ltd. as a subsidiary |
| February 2014 |
Launched LEUPRORELIN ACETATE FOR INJECTION KIT “ASKA”, an Endometriosis, uterine fibroids, and prostate cancer agent |
| September 2014 |
Launched CANDESARTAN TABLETS “ASKA”, an antihypertensive agent |
| October 2015 |
10th Anniversary of ASKA Pharmaceutical. Co., Ltd. |
| October 2015 |
Transferred manufacturing and marketing rights, and marketing approval of the antithyroid agents MERCAZOLE TABLETS, MERCAZOLE Injection, and PROPACIL TABLETS from Chugai Pharmaceutical Co., Ltd. |
| February 2016 |
Completed the Fourth Pharmaceutical Manufacturing Building in Iwaki Factory |
| April 2016 |
Launched LUTEUM VAGINAL SUPPOSITORIES, infertility agent |
| November 2016 |
Launched RIFXIMA TABLETS, a hepatic encephalopathy agent |
| October 2018 |
Jointly with Omnicare Drugs India Private Limited, invested in NeoASKApharma Private Limited in India. |
| December 2018 |
Launched FREWELL Combination Tablets LD “ASKA”, Combination Tablets ULD “ASKA”, a dysmenorrhea agent |
| March 2019 |
Launched RELUMINA tablets, uterine fibroids agent (Indication for endometriosis added in December 2021) |
| February 2020 |
Transferred rights related to manufacturing and marketing approval for “Magsent Injection”, “Magsent Injection Syringe”, indicated for preventing uterine contraction, and “IV MAGNESOL” which is indicated for the prevention and treatment of eclampsia from TOA Biopharma Co., Ltd |
| April 2020 |
Relocated Kawasaki Research Center to Shonan Health Innovation Park Initiated as Shonan Research Center |
| June 2020 |
100th anniversary |
| June 2020 |
Established Mint＋ Health Lab for Women’s health |
| June 2020 |
Launched THYRADIN-S Injection, a Hypothyroidism agent |
| January 2021 |
Vietnamese company, Ha Tay Pharmaceutical Joint Stock Company became an equity method affiliated company |
| April 2021 |
Established ASKA Pharmaceutical Holdings Co., Ltd. |
| April 2021 |
Established the London Office in England as our international representative office |
| June 2021 |
Appointed Sohta Yamaguchi as President |
| June 2022 |
Launched DroEthi Combination Tablet “ASKA”, a dysmenorrhea agent |